Exon 45 skipping is the most common single-exon target in Duchenne muscular dystrophy, affecting roughly 8 percent of patients, and approved therapy options for this specific target have remained limited, with little clinical data in humans. Entrada Therapeutics reported positive results Tuesday from the first cohort of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45, its exon-skipping candidate delivered via the company’s Endosomal Escape Vehicle (EEV) technology. The headline finding is early, drawn from a small first cohort, but in a disease where the exon 51-targeting drugs like eteplirsen received accelerated approval on sparse dystrophin signal, even a clean Phase 1/2 cohort readout moves the needle on program viability.

ENTR-601-45 works by delivering phosphorodiamidate morpholino oligomers intracellularly with greater efficiency than conventional PMO chemistry, aiming to restore the dystrophin reading frame and produce a truncated but functional protein. The EEV platform is the design bet here: standard PMO delivery to muscle tissue is notoriously inefficient, and the company’s argument is that endosomal escape is the rate-limiting step. Whether the first-cohort data show dystrophin production at levels meaningful for muscle function is what the 8-K does not specify, since the press release is furnished as an exhibit rather than summarized in the filing itself.

The trial is designed to enroll up to 24 ambulatory participants aged 4 to 20, dosed intravenously every six weeks in a randomized, double-blind, placebo-controlled structure. A first-cohort readout in a study of that size is a safety and preliminary biomarker signal, not a pivotal efficacy dataset. The exon 51 approvals set a regulatory precedent that dystrophin immunofluorescence and Western blot data, even from small numbers, can support accelerated pathways, which is the framework Entrada will be threading if later cohorts hold up.

The number to watch in subsequent disclosures is dystrophin protein expression in muscle biopsy, specifically whether ENTR-601-45 produces levels that meaningfully exceed what standard PMO delivery achieves, since the EEV platform’s entire differentiation rests on that comparison.

Source link: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000057/trda-20261014.htm

ENTR-601-45: the facts in one place

  • Also written: ENTR-601-45-201, ELEVATE-45-201
  • Sponsor: Entrada Therapeutics, Inc.
  • Mechanism: Endosomal Escape Vehicle (EEVâ„¢)-conjugated phosphorodiamidate morpholino oligomer inducing exon 45 skipping to restore mRNA reading frame and enable production of truncated functional dystrophin protein
  • Indication studied: Duchenne muscular dystrophy amenable to exon 45 skipping
  • Phase: Phase 1/2
  • Enrollment: 24
  • Primary endpoint: Overall safety and tolerability (Cohort 1)
  • Headline result: Cohort 1 (5 mg/kg): favorable safety and tolerability; 0.10% mean increase in dystrophin production; 0.15% mean increase in exon skipping; no functional benefit observed
  • Registry identifier: NCT07038824, 2024-517499-39
  • Current status: Phase 1/2 trial ongoing; Cohort 1 topline results reported October 14, 2026; Cohort 2 enrollment complete with data anticipated first half of 2027
  • UK authorization to initiate ELEVATE-45-201: March 24, 2025
  • EU authorization to initiate ELEVATE-45-201: May 28, 2025
  • Cohort 1 positive topline results announced: October 14, 2026
  • Cohort 2 data anticipated: first half of 2027
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.